On February 5, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (liso-cel, BREYANZI, Bristol Myers Squibb), a chimeric antigen receptor (CAR) T cell therapy, for adult patients with certain types of large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have not responded to, or who have relapsed after, at least two other types of systemic treatment. This is the fourth CAR T cell therapy approved for certain types of non-Hodgkin lymphoma (NHL).
“People battling relapsed or refractory large B-cell lymphoma continue to face a challenging treatment journey, both physically and emotionally,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “lisocabtagene maraleucel is an innovative treatment that offers a new option for patients, and another reason for this community to maintain hope for the future.”
For more information on the FDA approval of lisocabtagene maraleucel (BREYANZI), visit the FDA’s website. To learn more about treatment options for DLBCL, visit the DLBCL Learning Center.
Update on CAR T Cell Therapy for Patients with Lymphoma Webinar
Tuesday, March 2, 2021 | 3:30 PM – 4:30 PM ET
Javier Munoz, MD, MS, FACP
Mayo Clinic, Arizona
Anne Beaven, MD
UNC Lineberger Comprehensive Cancer Center
